DUTCH Test Rate-of-Change Interpretation: What Your Results Actually Mean

What the DUTCH Test Actually Measures

The DUTCH test is not a serum hormone panel. It captures hormone metabolites excreted into urine over specific time windows, giving a 24-hour metabolic picture that blood draws cannot replicate. The panel reports free cortisol, free cortisone, cortisol metabolites (THF, allo-THF, THE), DHEA-S, testosterone and its metabolites, estrone (E1), estradiol (E2), estriol (E3), progesterone metabolites (PDG, 5-pregnanediol), and several phase II conjugates tied to methylation and glucuronidation pathways.

Why Metabolites Matter More Than Parent Hormones

A serum estradiol reading of 80 pg/mL tells you the circulating level. The DUTCH test tells you where that estradiol goes after your liver processes it. Does it convert preferentially to 2-hydroxyestrone (2-OHE1), the less biologically active pathway, or to 16α-hydroxyestrone (16α-OHE1), the pathway associated with higher estrogenic tissue stimulation?

A 2022 review in the Journal of Clinical Endocrinology and Metabolism noted that urinary estrogen metabolite ratios provide clinically actionable information beyond serum estradiol alone, particularly for breast cancer risk stratification in postmenopausal women on hormone therapy (JCEM, 2022).

The 2-OHE1:16α-OHE1 ratio above 2.0 is the threshold most functional medicine practitioners use as a favorable methylation signal, though this target is derived from observational data rather than a randomized controlled trial.

The Four Collection Windows and What Each Reveals

• Waking sample (before rising): Baseline free cortisol and cortisone before the cortisol awakening response fires.
• 2 hours post-wake: Peak of the cortisol awakening response (CAR). Should reach roughly 2-3x the waking value in a healthy HPA axis.
• Bedtime sample: Cortisol nadir. Elevated bedtime cortisol is one of the clearest DUTCH flags for HPA hyperactivity or chronic stress physiology.
• 2 am sample (optional): Detects nocturnal cortisol surges that are invisible on a standard four-point panel.

Precision Analytical, the manufacturer of the DUTCH test, publishes a clinical reference guide noting that the CAR magnitude is one of the most reproducible stress-axis biomarkers in the dried urine format (Precision Analytical, 2023).

Understanding Normal Ranges vs. Optimal Ranges

"Normal" on the DUTCH report means your result falls within the age- and sex-stratified reference interval derived from Precision Analytical's database of more than 30,000 specimens. "Optimal" is a narrower clinical target that some practitioners apply based on symptom resolution data and longevity-medicine consensus.

Normal Reference Intervals

Reference intervals on the DUTCH report are presented as shaded zones. A result that falls inside the gray zone is within the population-based normal range. A result below or above that zone is flagged. These intervals vary by:

• Biological sex
• Age decade (e.g., premenopausal women 30-39 vs. Perimenopausal women 45-54)
• Time of collection (the bedtime cortisol interval is much lower than the waking interval)

The Endocrine Society's 2023 clinical practice guideline on adrenal insufficiency uses serum cortisol as the primary diagnostic standard, but acknowledges that 24-hour urinary cortisol metabolites provide complementary information when adrenal reserve is borderline (Endocrine Society CPG, 2023).

Optimal Ranges: Where Population Normal Ends and Clinical Target Begins

Optimal ranges are not regulatory definitions. They represent the zone within the normal interval where symptom burden is lowest and metabolic function appears best supported, based on clinical observation and the limited controlled data available.

For cortisol:

• Free cortisol (waking): 6-20 ng/mg creatinine for women, 8-25 ng/mg creatinine for men (population normal). The clinical optimal target most practitioners use is the upper half of these ranges when fatigue or HPA hypofunction symptoms are present.
• Total cortisol metabolites (THF + allo-THF + THE): Values in the lower quartile of the reference range combined with low DHEA-S suggest adrenal hypofunction worth investigating.

For DHEA-S:

A 2011 meta-analysis in the BMJ (N = 16 observational studies) found that low DHEA-S in adults over 50 correlated with higher all-cause mortality risk, though causality was not established (BMJ, 2011). The DUTCH DHEA-S value should be interpreted alongside the serum DHEA-S, since the dried urine metabolite and the serum measurement are not interchangeable.

For estrogens in women on HRT:

The NAMS (North American Menopause Society) 2022 position statement on hormone therapy does not endorse a specific urinary estrogen metabolite target, but acknowledges that methylation pathway monitoring may inform estrogen dose adjustments in clinical practice (NAMS, 2022).

Rate-of-Change Interpretation: The Core Clinical Skill

A single DUTCH result is a snapshot. Rate-of-change analysis compares two or more serial results taken under consistent conditions (same time of day, same hydration status, same collection protocol) after a defined intervention window.

The following framework is used by the HealthRX medical team to evaluate serial DUTCH results:

The HealthRX 3-Vector DUTCH Review

1. Direction: Did the marker move in the intended direction after the protocol change?
2. Magnitude: Is the shift clinically meaningful (more than 15% change for cortisol metabolites; more than 20% for estrogen metabolite ratios) or within assay noise?
3. Symmetry: Did upstream and downstream metabolites shift together, or did one move without the other (suggesting a conversion block or enzyme induction)?

This three-vector approach prevents over-interpreting normal assay variation and under-interpreting genuine metabolic shifts.

What Constitutes a Meaningful Change

Precision Analytical reports an intra-assay coefficient of variation (CV) below 8% for most analytes and an inter-assay CV below 12%. This means:

• A change of less than 10% in any single analyte between two serial tests is within the expected technical noise window.
• A consistent directional shift of 20% or more across two serial results separated by 8-12 weeks is clinically significant.
• A 2-OHE1:16α-OHE1 ratio that moves from 1.4 to 2.2 after adding 400 mg/day of DIM (diindolylmethane) represents a meaningful methylation shift worth sustaining.

A 2021 study published in Integrative Cancer Therapies (N = 47 women, 12-week intervention) found that DIM supplementation increased the 2-OHE1:16α-OHE1 ratio by a mean of 0.68 units (P<0.01), with the largest shifts in women who entered the study with a baseline ratio below 1.5 (Integrative Cancer Therapies, 2021).

Cortisol Rate-of-Change Patterns

Three patterns appear most commonly on serial DUTCH cortisol review:

Pattern 1: Downward slope across all four collection points This suggests progressive HPA suppression. Common causes include exogenous glucocorticoid use, prolonged caloric restriction, or overtraining syndrome. The bedtime cortisol falls first, followed by the waking and post-wake values as suppression deepens.

Pattern 2: Elevated bedtime cortisol with normal waking values (flattening) The diurnal slope flattens. Waking cortisol stays within range, but bedtime cortisol fails to drop below 1.5 ng/mg creatinine. This is the most common HPA pattern seen in insomnia, chronic psychological stress, and shift-work sleep disorder. A 2020 paper in Psychoneuroendocrinology (N = 183) confirmed that a flattened diurnal cortisol slope correlates with increased inflammatory markers and worse metabolic outcomes at 5-year follow-up (Psychoneuroendocrinology, 2020).

Pattern 3: Low CAR with normal total daily output The waking value is low, the 2-hour value does not rise adequately, but total daily cortisol metabolites are within range. This specific pattern points to CAR blunting rather than true adrenal insufficiency and is seen frequently in burnout and post-viral fatigue states.

Sex Hormone Rate-of-Change After Hormone Therapy Initiation

When a patient starts testosterone therapy (TRT in men, low-dose T in women) or progesterone supplementation, the DUTCH retest at 8-12 weeks should show:

• Men on TRT: Total testosterone metabolites (androsterone + etiocholanolone) rising into the upper half of the reference range. Free testosterone on the DUTCH is not the same as serum free testosterone; both should be tracked in parallel. If total metabolites rise but estrogen metabolites (specifically estradiol downstream metabolites) also rise disproportionately, aromatase activity warrants evaluation.
• Women on progesterone: PDG (pregnanediol glucuronide) rising above 1,000 ng/mg creatinine on a waking sample when using oral micronized progesterone 100-200 mg at bedtime. Topical progesterone absorbs poorly through skin and rarely moves PDG meaningfully.
• Women on estradiol patches or gels: E1 and E2 metabolites rising proportionately. The 2-OHE1:16α-OHE1 ratio should be tracked at each retest.

The ACOG Committee Opinion 659 acknowledges that progesterone delivery route affects systemic absorption significantly, noting that vaginal and oral routes produce measurable serum levels while transdermal cream does not reliably achieve endometrial protection levels (ACOG, 2016).

DHEA-S and Adrenal Aging: Serial Tracking Over Time

DHEA-S peaks around age 25 and declines approximately 2% per year thereafter. The DUTCH DHEA-S metabolite (measured as the sum of DHEA and its downstream androgenic metabolites) provides a urinary proxy for adrenal androgen output.

What a Declining DHEA-S Trajectory Means

A drop of more than 20% in DHEA-S metabolites between two annual DUTCH tests, in the absence of new medication (especially glucocorticoids), warrants clinical attention. This rate of decline exceeds expected physiological aging and may reflect:

• Subacute HPA suppression from high-dose inhaled corticosteroids (budesonide, fluticasone)
• Adrenal autoimmunity (anti-21-hydroxylase antibodies should be checked)
• Significant caloric deficit or protein insufficiency

A 2019 review in Frontiers in Endocrinology noted that DHEA supplementation in adults over 60 with confirmed DHEA deficiency (serum DHEA-S below 100 µg/dL in men, below 70 µg/dL in women) improved subjective well-being scores in 6 of 8 randomized trials reviewed (Frontiers in Endocrinology, 2019).

DHEA Supplementation Monitoring Protocol

If DHEA supplementation (typically 10-50 mg/day oral) is initiated, the 8-week DUTCH retest should show DHEA-S metabolites rising toward the mid-range of the age-adjusted reference interval. A rise above the upper reference limit suggests the dose is too high. Women are particularly sensitive to androgenic side effects (acne, hair shedding) when DHEA metabolites exceed the upper quartile of the female reference range.

Phase II Metabolism: Methylation and Glucuronidation Tracking

The DUTCH test reports downstream estrogen metabolites that reflect two detoxification pathways in the liver. Phase I produces 2-OHE1, 4-OHE1, and 16α-OHE1 from estradiol. Phase II methylates these intermediates (via COMT enzyme) or glucuronidates them for urinary excretion.

2-Methoxyestrone as a COMT Activity Marker

2-Methoxyestrone (2-MeOE1) appears on the expanded DUTCH report. A low 2-MeOE1 relative to 2-OHE1 indicates that 2-OHE1 is not being adequately methylated, likely from COMT single nucleotide polymorphisms (SNPs), low magnesium, or low SAMe availability. This is actionable: magnesium glycinate 300-400 mg/day and methyl-B12/methylfolate supplementation can shift 2-MeOE1 upward in 8-12 weeks.

4-OHE1: The Pathway That Warrants Closest Monitoring

4-Hydroxyestrone (4-OHE1) is the estrogen metabolite most associated with DNA adduct formation in breast tissue. When 4-OHE1 is detectable and elevated relative to 2-OHE1, the clinical priority shifts to maximizing phase II methylation via COMT support rather than simply improving the 2:16 ratio.

A 2015 study in Cancer Epidemiology, Biomarkers and Prevention (N = 1,135 postmenopausal women) found that the 4-OHE1 to 2-OHE1 ratio was a stronger predictor of breast cancer risk than the 2:16 ratio alone (Cancer Epidemiology, Biomarkers and Prevention, 2015).

Common Interpretation Errors and How to Avoid Them

Comparing Results Across Different Hydration States

Creatinine correction on the DUTCH report adjusts for dilution, but extreme over-hydration (urine output above 3 L/day) or under-hydration still skews results. Patients should be instructed to follow normal fluid intake on collection days and avoid high-volume fluid loading the night before.

Changing Multiple Variables Between Serial Tests

If a patient starts DHEA, changes their sleep schedule, begins a new exercise program, and modifies their diet between DUTCH tests, the rate-of-change data cannot be attributed to any single intervention. Protocols should change one variable at a time when the goal is mechanistic interpretation of serial results.

Treating DUTCH as a Replacement for Serum Testing

DUTCH metabolite values and serum hormone values are complementary, not interchangeable. Serum estradiol, testosterone, LH, FSH, and SHBG remain the standard for diagnosing hypogonadism, confirming menopause, or dosing hormone therapy per the Endocrine Society guidelines. The DUTCH test adds the metabolic layer that serum cannot provide.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men specifies serum total and free testosterone (LC-MS/MS method) as the diagnostic standard and does not endorse dried urine testing as a replacement for diagnosis (Endocrine Society, 2018).

When to Retest and How to Structure a Serial DUTCH Protocol

A structured serial testing protocol is the only way to use the DUTCH test's rate-of-change capability. The HealthRX medical team follows these intervals:

• Baseline (before any protocol change): Establishes the starting pattern.
• 8-12 weeks post-intervention: First efficacy check. Cortisol and androgen metabolites move within this window if the intervention is working.
• 6 months post-intervention: Confirms stability. Estrogen methylation ratios and DHEA-S trajectory are assessed here.
• Annual maintenance: Tracks longitudinal adrenal aging and detects new pattern shifts before symptoms appear.

For women on HRT specifically, a DUTCH retest at 3 months after any dose change is appropriate given that estradiol metabolite patterns stabilize within 6-8 weeks of reaching a steady-state dose. A serum estradiol draw at the same time point allows cross-referencing delivery adequacy.